- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-6277
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Immunotherapy in Hepatocellular Carcinoma ; volume:22 ; number:10 ; day:23 ; month:8 ; year:2021 ; pages:1-19 ; date:10.2021
Current treatment options in oncology ; 22, Heft 10 (23.8.2021), 1-19, 10.2021
- Creator
-
Fulgenzi, Claudia A. M.
Talbot, Thomas
Murray, Sam M.
Silletta, Marianna
Vincenzi, Bruno
Cortellini, Alessio
Pinato, David J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-021-00886-5
- URN
-
urn:nbn:de:101:1-2021121721044457921260
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fulgenzi, Claudia A. M.
- Talbot, Thomas
- Murray, Sam M.
- Silletta, Marianna
- Vincenzi, Bruno
- Cortellini, Alessio
- Pinato, David J.
- SpringerLink (Online service)
Other Objects (12)
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Immunotherapy of hepatocellular carcinoma with small double-stranded RNA
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Immunotherapy of hepatocellular carcinoma with small double-stranded RNA
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Immunotherapy of hepatocellular carcinoma with small double-stranded RNA
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma